Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C17H15ClO4 |
|||
Molecular Weight | 318.75 | CAS No. | 42017-89-0 | |
Solubility (25°C)* | In vitro | DMSO | 64 mg/mL (200.78 mM) | |
Ethanol | 16 mg/mL (50.19 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides. | |
---|---|---|
Targets |
|
|
In vitro | Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR[1]. | |
In vivo | Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of Fenofibric acid on EPC mobilization in the OIR model is PPARα-dependent.Fenofibric acid Inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. Fenofibric acid decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina[1]. |
Cell Assay: |
|
---|---|
Animal Study: |
|
|
Peroxisome Proliferator-Activated Receptor α Activation Protects Retinal Ganglion Cells in Ischemia-Reperfusion Retinas [ Front Med (Lausanne), 2021, 8:788663] | PubMed: 35004756 |
Immediate-released pelletized solid dispersion containing fenofibrate: Formulation, in vitro characterization, and bioequivalence studies in experimental beagle dogs. [ Int J Pharm, 2019, 570:118661] | PubMed: 31491482 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.